1. Home
  2. ENTG vs GMAB Comparison

ENTG vs GMAB Comparison

Compare ENTG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Entegris Inc.

ENTG

Entegris Inc.

N/A

Current Price

$109.92

Market Cap

18.1B

Sector

Industrials

ML Signal

N/A

Logo Genmab A/S ADS

GMAB

Genmab A/S ADS

N/A

Current Price

$31.04

Market Cap

21.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTG
GMAB
Founded
1966
1999
Country
United States
Denmark
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1B
21.1B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ENTG
GMAB
Price
$109.92
$31.04
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$117.56
$40.00
AVG Volume (30 Days)
3.5M
1.9M
Earning Date
02-10-2026
02-17-2026
Dividend Yield
0.36%
N/A
EPS Growth
26.59
132.41
EPS
1.90
25.10
Revenue
$3,222,508,000.00
$3,845,670,022.00
Revenue This Year
$0.24
$24.85
Revenue Next Year
$6.09
$16.51
P/E Ratio
$58.08
$1.23
Revenue Growth
0.59
29.57
52 Week Low
$60.75
$17.24
52 Week High
$124.00
$35.43

Technical Indicators

Market Signals
Indicator
ENTG
GMAB
Relative Strength Index (RSI) 55.76 40.88
Support Level $108.56 $32.21
Resistance Level $121.92 $33.52
Average True Range (ATR) 5.43 0.78
MACD -1.59 -0.33
Stochastic Oscillator 28.66 2.61

Price Performance

Historical Comparison
ENTG
GMAB

About ENTG Entegris Inc.

Entegris is a leading supplier of purification solutions and advanced materials. The vast majority of sales are to the semiconductor industry. The majority of revenue comes from semiconductor fabricators, but the company sells to all areas of the semiconductor manufacturing supply chain including equipment and engineering, chemicals and materials, and distributors. Entegris specializes in materials science and materials purity, both of which are crucial in the semiconductor manufacturing process.

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Share on Social Networks: